Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Defined term · Evidence assessment

Risk of bias

The extent to which features of a study’s design or conduct could produce an effect estimate that systematically departs from the truth. Assessed at the level of the individual study and carried into…

Document identifier
CEI-GT-010
Series
Defined term
Version
1.0
Published
30 Jul 2026
Last reviewed
30 Jul 2026
Certainty
Not rated

§1Risk of bias

§1.1Also known as

Study limitations

§1.2Category

Evidence assessment — Terms describing how the Institute judges and reports the strength of evidence.

§1.3Related terms

  • Allocation concealment — The prevention of foreknowledge of the next allocation by the person enrolling a participant. Distinct from blinding, which concerns knowledge after allocation, and…
  • Blinding — The withholding of knowledge of assignment from participants, investigators, outcome assessors or analysts. The Institute records who was blinded rather than describing…
  • Attrition — Loss of participants from a trial before its primary analysis timepoint. Differential attrition between arms threatens the comparability that randomisation established.
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.